Mumbai: Sun Pharmaceutical Industries Limited, based in India, has received final approval from the United States Food and Drug Administration (FDA) for the company’s application for Nicardipine Hydrochloride Injections (HCI), which is a short-term treatment for hypertension.

Daiichi-Ranbaxy has tied up with Canada-based transdermal drug development firm Nuvo Research Inc to supply a topical wound healing agent Oxoferin in some Asian countries.

Eslicarbazepine acetate (Zebinix), a once-daily pill to treat epileptic seizures  by Eisai has been launched in UK.

Wyeth's Prevnar vaccine trials were suspended in India last year after reports of infant death

Ranbaxy Science Foundation (RSF), a non-profit organization set-up by Ranbaxy Laboratories Limited (RLL), has honoured Indian researchers in pharma and medicine for their outstanding contributions in its 21st Annual Research Awards for the year 2008

Swiss drug major Novartis AG is increase its research and development activities in China by investing a USD 1 billion investment over the next five years, the company said in a press release.

Six Indian companies are facing the risk of getting blacklisted and their products banned in Sri Lankan pharmaceutical market for allegedly marketing contaminated drug products including vaccines.

Intravenous (IV) H1N1 swine flu drug peramivir from BioCryst Pharmaceuticals, Inc. has been given approval to use in emergencies by US FDA.

Testosterone gel Fortesta to enhance sexual libido in testostrone deficient men by Endo Pharmaceuticals Holdings Inc has been delayed approval in US.

Indacaterol (QAB149) has already received a positive regulatory opinion in Europe